Literature DB >> 24936231

A κ Opioid Pharmacophore Becomes a Spinally Selective κ-δ Agonist When Modified with a Basic Extender Arm.

Ye Tang1, Jie Yang1, Mary M Lunzer1, Michael D Powers1, Philip S Portoghese1.   

Abstract

We have explored the concept of a molecular extender arm attached to a κ opioid agonist pharmacophore 3 (ICI-199,441) in an effort to potentially interact with a complementary group on a neighboring opioid receptor. The molecular arm containing a terminal amine group was lengthened incrementally from 11 up to 18 atoms. Increasing the number of atoms in the arm produced virtually no change in the mouse intracerebroventricular (i.c.v.) antinociceptive potency. In contrast, the intrathecal (i.t.) potency of 6 (KDA-16) with a 16-atom arm was dramatically increased, as reflected by its antinociceptive i.c.v./i.t. ED50 ratio of ∼130. Further lengthening led to a decreased ED50 ratio. In vivo selective antagonist studies of KDA-16 revealed that κ and δ opioid receptors were responsible for the greatly enhanced i.t. potency. Calcium release experiments in HEK-293 cells suggested that KDA-16 selectively activate κ-δ heteromers. These data are consistent with the reported possible presence of heteromeric κ-δ opioid receptors in mouse spinal cord but not in the brain. The use of a molecular extender arm may be useful for developing spinally selective analgesics.

Entities:  

Keywords:  Opioid receptors; heteromers; molecular extender arm

Year:  2010        PMID: 24936231      PMCID: PMC4056884          DOI: 10.1021/ml1001294

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  18 in total

1.  Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties.

Authors:  S R George; T Fan; Z Xie; R Tse; V Tam; G Varghese; B F O'Dowd
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

2.  Coexistence of kappa- and delta-opioid receptors in rat spinal cord axons.

Authors:  M W Wessendorf; J Dooyema
Journal:  Neurosci Lett       Date:  2001-02-09       Impact factor: 3.046

3.  Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer.

Authors:  Danxin Wang; Xiaochun Sun; Laura M Bohn; Wolfgang Sadée
Journal:  Mol Pharmacol       Date:  2005-03-18       Impact factor: 4.436

4.  A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.

Authors:  Maria Waldhoer; Jamie Fong; Robert M Jones; Mary M Lunzer; Shiv K Sharma; Evi Kostenis; Philip S Portoghese; Jennifer L Whistler
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-02       Impact factor: 11.205

5.  Central effects of the potent and highly selective mu opioid antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) in mice.

Authors:  K Gulya; M Kriván; N Nyolczas; Z Sarnyai; G L Kovács
Journal:  Eur J Pharmacol       Date:  1988-06-10       Impact factor: 4.432

6.  Standard opioid agonists activate heteromeric opioid receptors: evidence for morphine and [d-Ala(2)-MePhe(4)-Glyol(5)]enkephalin as selective μ-δ agonists.

Authors:  Ajay S Yekkirala; Alexander E Kalyuzhny; Philip S Portoghese
Journal:  ACS Chem Neurosci       Date:  2009-11-25       Impact factor: 4.418

7.  Structure/activity studies related to 2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted- ethyl]acetamides: a novel series of potent and selective kappa-opioid agonists.

Authors:  J J Barlow; T P Blackburn; G F Costello; R James; D J Le Count; B G Main; R J Pearce; K Russell; J S Shaw
Journal:  J Med Chem       Date:  1991-11       Impact factor: 7.446

8.  Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists.

Authors:  P S Portoghese; A W Lipkowski; A E Takemori
Journal:  Life Sci       Date:  1987-03-30       Impact factor: 5.037

9.  A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors.

Authors:  Shijun Zhang; Ajay Yekkirala; Ye Tang; Philip S Portoghese
Journal:  Bioorg Med Chem Lett       Date:  2009-11-04       Impact factor: 2.823

10.  Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.

Authors:  Yaguo Zheng; Eyup Akgün; Kaleeckal G Harikumar; Jessika Hopson; Michael D Powers; Mary M Lunzer; Laurence J Miller; Philip S Portoghese
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

View more
  8 in total

1.  The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain.

Authors:  Diana Vivian Atigari; Kelly Frances Paton; Rajendra Uprety; András Váradi; Amy Frances Alder; Brittany Scouller; John H Miller; Susruta Majumdar; Bronwyn Maree Kivell
Journal:  Neuropharmacology       Date:  2020-12-28       Impact factor: 5.250

2.  MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats.

Authors:  Diana V Atigari; Rajendra Uprety; Gavril W Pasternak; Susruta Majumdar; Bronwyn M Kivell
Journal:  Neuropharmacology       Date:  2019-02-13       Impact factor: 5.250

3.  Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy.

Authors:  Kevin J Frankowski; Michael P Hedrick; Palak Gosalia; Kelin Li; Shenghua Shi; David Whipple; Partha Ghosh; Thomas E Prisinzano; Frank J Schoenen; Ying Su; S Vasile; Eduard Sergienko; Wilson Gray; Santosh Hariharan; Loribelle Milan; Susanne Heynen-Genel; Arianna Mangravita-Novo; Michael Vicchiarelli; Layton H Smith; John M Streicher; Marc G Caron; Lawrence S Barak; Laura M Bohn; Thomas D Y Chung; Jeffrey Aubé
Journal:  ACS Chem Neurosci       Date:  2012-01-20       Impact factor: 4.418

Review 4.  Strategies towards safer opioid analgesics-A review of old and upcoming targets.

Authors:  Balazs R Varga; John M Streicher; Susruta Majumdar
Journal:  Br J Pharmacol       Date:  2021-11-26       Impact factor: 9.473

5.  Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior.

Authors:  András Váradi; Gina F Marrone; Shainnel O Eans; Michelle L Ganno; Joan J Subrath; Valerie Le Rouzic; Amanda Hunkele; Gavril W Pasternak; Jay P McLaughlin; Susruta Majumdar
Journal:  ACS Chem Neurosci       Date:  2015-09-14       Impact factor: 4.418

Review 6.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

7.  A DFT and semiempirical model-based study of opioid receptor affinity and selectivity in a group of molecules with a morphine structural core.

Authors:  Tamara Bruna-Larenas; Juan S Gómez-Jeria
Journal:  Int J Med Chem       Date:  2012-12-13

8.  Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects.

Authors:  Morgan Le Naour; Mary M Lunzer; Michael D Powers; Alexander E Kalyuzhny; Michael A Benneyworth; Mark J Thomas; Philip S Portoghese
Journal:  J Med Chem       Date:  2014-07-18       Impact factor: 7.446

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.